Trade Cryoport, Inc. - CYRX CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.12
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022207 %(-$4.44)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02221%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000015 %(-$0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00002%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022207 %
  (-$4.44)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000015 %
  (-$0.00)

Key Stats

• Prev. Close: 17.25
• Open: 17.19
• 1-Year Change: 80.95%
• Day's Range: 17.19 - 17.48

Trade Cryoport, Inc. - CYRX

About CryoPort Inc

Cryoport, Inc. is a provider of integrated temperature-controlled supply-chain solutions to the biopharma/pharma, animal health, and reproductive medicine markets. The Company provides supply chain technologies and services through its brands, such as Cryoport Systems, CryoStork, MVE Biological Solutions, CRYOPDP, and CRYOGENE. The Company's products include Cryoport Express Shippers, Cryoport ELITE Shippers, Cryoport Cryosphere, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature Controlled Logistics, CRYOPDP Direct to Patient Solutions, CRYOPDP Control Tower Solution, MVE Biological Solutions Fusion Cryogenic Freezers and MVE Biological Solutions Vario Cryogenic Freezer. It operates primarily in Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC). Its wholly owned subsidiaries include Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions, US LLC, and Cryoport Netherlands B.V.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, CryoPort Inc revenues increased from $78.7M to $222.6M. Net loss applicable to common stockholders increased from $75M to $283.7M. Revenues reflect Americas segment increase from $49.6M to $120.3M, Europe & Middle East & Africa (EMEA) segment increase from $20.3M to $59.3M. Higher net loss reflects General and administrative - Balancing v increase of 74% to $85.1M (expense).

Equity composition

Common Stock $.001, 2/11, 250M auth., 26,723,426 issd. Insiders own approx. 0.09%. 02/10, 1-for-10 reverse split. 02/10, Exchange changed from NASDAQ to OTC.05/15, 1-for-12 Reverse stock split.